Tokai Pharmaceuticals Inc. (TKAI) 11.52 $TKAI Tokai

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:43 PM

Tokai Pharmaceuticals Inc. (TKAI) 11.52 $TKAI

Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth
Business Wire - Mon Apr 20, 3:01PM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and migration of human pancreatic ductal adenocarcinoma (PDAC) cells.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Medivation Chief Commercial Officer, to its Board of Directors
Business Wire - Mon Apr 13, 3:01PM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced the appointment of Cheryl Cohen, the former Chief Commercial Officer of Medivation, Inc., to its Board of Directors.
MDVN: 128.88 (+0.29), TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals to Present at Upcoming Conferences
Business Wire - Fri Apr 10, 6:00AM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that it will present at two upcoming conferences:
TKAI: 11.52 (-0.35)

Tokai Pharma and Qiagen expand collaboration on prostate cancer drug companion diagnostic
Seeking Alpha - at Seeking Alpha - Mon Mar 16, 3:42PM CDT

TKAI: 11.52 (-0.35), QGEN: 24.93 (-0.15)

Tokai Pharmaceuticals Announces Expansion to Collaboration with Qiagen on the Development of an AR-V7 Companion Diagnostic
Business Wire - Mon Mar 16, 3:00PM CDT
--Tokai Granted Exclusive Right to Qiagen's Circulating Tumor Cell (CTC) Enrichment Technology for use with a Companion Diagnostic Paired with Galeterone
TKAI: 11.52 (-0.35)

QIAGEN Expands Leadership in Liquid Biopsies with New Circulating Tumor Cell Technology for Development of Companion Diagnostics
PR Newswire - Mon Mar 16, 3:00PM CDT
-- Acquisition of technology from AdnaGen enables use of innovative, non-invasive blood tests to analyze circulating tumor cells (CTCs) for personalized healthcare
TKAI: 11.52 (-0.35), QGEN: 24.93 (-0.15)

Tokai Pharmaceuticals reports 4Q loss
Automated Insights - Thu Mar 12, 7:37AM CDT
CAMBRIDGE, Mass. (AP) _ Tokai Pharmaceuticals Inc. (TKAI) on Thursday reported a loss of $6.2 million in its fourth quarter.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals beats by $0.06
Seeking Alpha - at Seeking Alpha - Thu Mar 12, 7:28AM CDT

TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Thu Mar 12, 7:00AM CDT
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter and year ended December 31, 2014.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals to Present at the Cowen and Company 35th Annual Health Care Conference
Business Wire - Mon Mar 02, 7:00AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Jodie Morrison, President and Chief Executive Officer, will provide a company overview at the Cowen and Company 35th Annual Health Care Conference in Boston, MA on Wednesday, March 4 at 8am ET.
TKAI: 11.52 (-0.35)

Asco-GU Preview: First-Line Prostate Cancer Chemo Not Dead Yet
EP Vantage - Seeking Alpha - Tue Feb 24, 8:03AM CST
As two leading prostate cancer drugs, Medivation ’s (NASDAQ: MDVN ) Xtandi and Johnson & Johnson ’s (NYSE: JNJ ) Zytiga , battle it out for dominance in the all-important pre-chemotherapy setting, a small study is set to...
MDVN: 128.88 (+0.29), JNJ: 100.43 (+0.13), TKAI: 11.52 (-0.35), SNY: 51.59 (+0.03)

Tokai Pharmaceuticals Provides Companion Diagnostic Update
Business Wire - Mon Jan 12, 8:30AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), today announced that it has entered into an agreement with the Johns Hopkins University related to the development of a companion diagnostic to determine the AR-V7 status of patients with castration-resistant prostate cancer (CRPC) for use with the Company's lead product, galeterone, which is in development for the treatment of AR-V7 positive metastatic CRPC.
TKAI: 11.52 (-0.35)

Stephen Buckley, Jr. Appointed to Tokai Board of Directors
Business Wire - Fri Jan 09, 7:16AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Stephen Buckley, Jr. has joined the company's board of directors and will serve as chair of the audit committee.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data Showing Activity in Patients with Castration-Resistant Prostate Cancer (CRPC) Including Those Showing a Variant Form of Prostate Cancer Resistant to Hormone Therapy
Business Wire - Wed Nov 19, 7:05AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) today announced updated interim results from its ongoing ARMOR2 Phase 2 clinical trial of galeterone in castration-resistant prostate cancer (CRPC) patients. These interim results from the trial support the potential of galeterone to treat CRPC expressing androgen receptor (AR) splice variants, including AR-V7. The presence of AR C-terminal loss generally, and AR-V7 specifically, has been linked to poor responsiveness to hormonal agents commonly used to treat CRPC.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals, Inc. (Nasdaq: TKAI) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Nov 14, 9:43AM CST
What:
TKAI: 11.52 (-0.35), NDAQ: 48.84 (+0.12)

Tokai Pharmaceuticals EPS of -$2.71
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:37AM CST

TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 7:02AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today reported company highlights and financial results for the quarter ended September 30, 2014.
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Announces Interim Phase 2 Data on Galeterone in Patients with Advanced Prostate Cancer to be Presented at the EORTC-NCI-AACR Symposium
Business Wire - Wed Nov 05, 7:01AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that updated, interim results from the company's ongoing Phase 2 clinical trial, ARMOR2, of its lead drug candidate, galeterone, in patients with castration resistant prostate cancer (CRPC) will be presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held November 18-21 in Barcelona, Spain. The presentation entitled, "Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2" will be presented by Mary-Ellen Taplin, M.D., Associate Professor of Medicine, Director of Genitourinary Oncology Clinical Research, Dana-Farber Cancer Institute, Harvard Medical School, and co-principal investigator of ARMOR2, as an oral presentation during the Plenary Session 2 on Wednesday, November 19, 2014 at 2:05 p.m. (CET).
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
Business Wire - Tue Nov 04, 7:02AM CST
Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced that Jodie Morrison, president and chief executive officer, will provide a company overview at two November investment conferences:
TKAI: 11.52 (-0.35)

Tokai Pharmaceuticals Presents Updated Phase 2 Data on Galeterone in Patients with Advanced Prostate Cancer at ESMO 2014
Business Wire - Mon Sep 29, 7:01AM CDT
--Updated Data Supports Development in Patients with Splice Variants
TKAI: 11.52 (-0.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Tools Arm Manufacturers in Additive Arena

Diving Headfirst into Additive Manufacturing Standards Additive manufacturing (AM)—it's not just another tech buzzword. It's revolutionizing everything from life-saving medical devices to cutting-edge aerospace components. But as with any game-changing innovation, there's a wild west era before standards reign in the chaos. Enter ANSI and America Makes, offering new...

Quorum Joins LIVE Coalition to Revolutionize Estate Planning

Shaking Up Estate Planning: Quorum Joins LIVE Coalition Here's a fresh shake-up in the world of estate planning. Quorum Federal Credit Union has thrown its hat into the ring as the latest member of the LIVE Coalition, a band of financial, legal, and tech wizards putting estate plans on a modern track. This marks them as the 70th player to dive into this alliance, pushing...

Mitsubishi's Q3 Sales: SUVs Up, Mirage Out

You ever notice how the market treats innovation and tradition like they’re these ever-spinning plates in a circus act? Take Mitsubishi Motors North America (MMNA). Their third-quarter report's got me both nodding in approval and scratching my head. Sure, they sold 18,543 vehicles—down 5.6% from the previous year. But don’t write 'em off just yet. The slumping...

Maternal Health Index: A New Tool With Big Ambitions

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...

Cannatrol and Veterans Nonprofit Unite for Healing

Veterans Find a New Ally in Cannabis Tech When two distinct worlds collide for a cause, it can create waves of change much bigger than simple collaboration. That's exactly what's happening with Cannatrol and Operation Green Healing, a partnership that could redefine support for our veterans. Cannatrol, renowned for its groundbreaking post-harvest cannabis technology, has...

Fiber Giants Unite to Boost Connectivity in Montana

Montana's Broadband Transformation Takes a Leap Folks in Northwest Montana, take note. Vero Fiber and MontanaSky have tied the knot, officially sealing a merger that doesn't just unite two reputable broadband providers but promises to shake up the internet game across the region. Just ask anyone who's tried to stream a movie during peak hours in Flathead Valley. A...

Karen Love's Retirement Marks End of an Era for TACHP

A Legacy Not Just Built, But Carved in Stone In the world of healthcare, folks like Karen Love don’t come around too often. She's stepping down from her post as President and CEO of Cook Children's Health Plan this month, and it feels like the end of a chapter for the Texas Association of Community Health Plans (TACHP). Love wasn't just an executive; she was a mover and...

Nukleus Launches Unified Platform for Athletes' Business

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...

October Becomes a Beacon for Grieving Families

October: A Month for Heartfelt Observance There's a profound resonance when October rolls around, especially for families who've faced the heartbreak of pregnancy or infant loss. Thanks to Postpartum Support International (PSI), the month serves as more than just a page in a calendar—it's a solidarity rallying cry for awareness and remembrance. The group's commitment to...

Fresh Leadership at Master Group: Langelier Steps In

Changing of the Guard: A Calculated Move It's not every day you see a company make a move as calculated and thoughtful as the one the Master Group just pulled. Rémy Langelier is set to transition into the shoes of CEO by early 2027, fresh off the heels of Louis St-Laurent. This isn't just any executive shuffle, folks—it's a strategic baton pass spawning an investment...